- /
- Supported exchanges
- / US
- / TWST.NASDAQ
Twist Bioscience Corp (TWST NASDAQ) stock market data APIs
Twist Bioscience Corp Financial Data Overview
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Twist Bioscience Corp (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Twist Bioscience Corp data using free add-ons & libraries
Get Twist Bioscience Corp Fundamental Data
Twist Bioscience Corp Fundamental data includes:
- Net Revenue: 392 M
- EBITDA: -112 748 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-02
- EPS/Forecast: -0.43
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Twist Bioscience Corp News
New
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
B-Body® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-t...
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole...
Twist Bioscience Annual Meeting: Shareholders Elect Directors, Approve Pay and EY Auditor Ratification
Twist Bioscience logo Key Points All three director nominees—Keith Crandell, Jan Johannessen and Trynka Shineman Blake—were duly elected; the non‑binding advisory vote approving executive comp...
Cathie Wood buys $43 million of megacap tech stock
It’s been a rocky start to the year for Cathie Wood, the head of Ark Investment Management. As of Feb. 6, Wood’s flagship Ark Innovation ETF (ARKK) was down 9.58% year to date, while the S&P 500 ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.